VIYASH259.00

Viyash Scientific Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSYATHARTHTHYROCARESUPRIYASTARSPARCSHILPAMEDRUBICONMcap ₹11,314 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-5.032.845.695.69
Return on Assets-1.922.014.854.85
Return on Capital Employed-0.018.6911.3811.38
Return on Invested Capital-0.016.028.187.64
Margins
EBITDA Margin4.4810.4319.0818.86
Operating Margin-0.016.1512.2512.25
Incremental Operating Margin52.5617.31
Pretax Margin-3.992.8610.2010.73
Net Income Margin-2.162.086.576.79
Net Income to Common Margin-2.621.415.185.44
FCF Margin-0.022.855.505.50
Additional
Effective Tax Rate45.8127.1935.6336.73
Dvd Payout Ratio-0.005.732.19
Sustainable Growth Rate-5.032.685.575.69
Incremental Operating Margin %52.5617.317.78
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.